Annual report · 2026 (year to date)

ME/CFS: state of the evidence 2026

What the Open Source Medicine Foundation research tracker holds on ME/CFS for 1 January to 21 November 2026: literature flow, registered trials, agents under study, catalogued biomarkers and cohorts. Every figure is computed from the public JSON files linked at the end of this page.

  1. Research Tracker
  2. Annual Reports
  3. ME/CFS: state of the evidence 2026
Contents:

Summary

75studies dated 2026 in the feed
148registered trials matched
37trials recruiting or active
11trials started in 2026
46biomarkers catalogued
4research cohorts indexed
Read this first. The literature feed is a rolling window of the 75 most recent PubMed results for this condition (currently spanning 4 September 2026 to 16 November 2026), not a complete census of 2026 publications. Monthly counts before the window opens are zero for that reason, not because nothing was published.

Literature indexed in 2026

The ME/CFS feed holds 75 PubMed records with a 2026 publication date (75 unique PMIDs) out of 75 records in the feed, drawn from 61 distinct journals. This is a substantial sample.

Studies indexed per month, 20261835JanFebMarAprMayJunJulAugSep 2026: 2424SepOct 2026: 3535OctNov 2026: 1616NovDec
Records by publication month, 2026. Grey month labels are in the future. Months before the feed window opened are zero by construction.

Top journals

Top journals, 2026Journal of translational medi…Journal of translational medicine: 55Journal of psychosomatic rese…Journal of psychosomatic research: 44International journal of mole…International journal of molecular sciences: 33Frontiers in public healthFrontiers in public health: 22Psychiatrische PraxisPsychiatrische Praxis: 22PloS onePloS one: 22Explore (New York, N.Y.)Explore (New York, N.Y.): 22MedicineMedicine: 22Advances in rehabilitation sc…Advances in rehabilitation science and practice: 11Journal of clinical medicineJournal of clinical medicine: 11
Journals with the most 2026 records in the feed (top 10; ties broken by first appearance).

Browse the live feed: ME/CFS research tracker. Weekly changes are in the research digest.

Clinical trials

148 of the 635 ClinicalTrials.gov records in the tracker snapshot (taken 2026-11-21) match ME/CFS (148 via the tracker's curated condition mapping). 37 are recruiting, not yet recruiting, enrolling by invitation or active; 11 list a 2026 start date and 35 had their registry record updated in 2026. Median planned or actual enrollment is 55 participants (147 trials report a figure).

By status

Trials by statusCompletedCompleted: 7676RecruitingRecruiting: 2222UnknownUnknown: 2020Active Not RecruitingActive Not Recruiting: 1010TerminatedTerminated: 99Not Yet RecruitingNot Yet Recruiting: 44WithdrawnWithdrawn: 44SuspendedSuspended: 22Enrolling By Invitati…Enrolling By Invitation: 11
Overall status as recorded on ClinicalTrials.gov at snapshot.

By phase

Trials by phaseNot applicableNot applicable: 9393Phase 2Phase 2: 2929Phase 1Phase 1: 1212Phase 4Phase 4: 88Phase 3Phase 3: 44Early phase 1Early phase 1: 22
"Not applicable" covers behavioural, device, rehabilitation and observational designs.

By sponsor type

Trials by sponsor typeAcademic / otherAcademic / other: 127127IndustryIndustry: 1212NIHNIH: 33Research networkResearch network: 22Other governmentOther government: 22US federal (non-NIH)US federal (non-NIH): 22
Lead-sponsor class from the registry; "Academic / other" is the registry's OTHER category.

Agents under investigation

Top agents by trial countRituximabRituximab: 55N-Acetylcysteine (NAC)N-Acetylcysteine (NAC): 33AcupunctureAcupuncture: 33Hydrogen WaterHydrogen Water: 33Sodium OxybateSodium Oxybate: 33Low-Dose Naltrexone (…Low-Dose Naltrexone (LDN): 22Melatonin Plus ZincMelatonin Plus Zinc: 22Neuromuscular Evaluat…Neuromuscular Evaluation: 22ActigraphyActigraphy: 22Blood TestBlood Test: 22
Interventions named in the most matched trials (top 10 of 195 distinct agents). A trial testing several agents counts once per agent.
AgentTrialsOf which active
Rituximab51
N-Acetylcysteine (NAC)31
Acupuncture31
Hydrogen Water30
Sodium Oxybate30
Low-Dose Naltrexone (LDN)22
Melatonin Plus Zinc20
Neuromuscular Evaluation20
Actigraphy20
Blood Test20

Trials starting in 2026

NCTTrialStatusPhaseStartSponsor
NCT07724834CD19-B Cell Depletion in PAIS-ME/CFS Patients
Inebilizumab
Not Yet RecruitingPhase 22026-12-01Charite University, Berlin, Germany
NCT07285473Low-Dose Naltrexone For ME/CFS: Dose-Finding
Low-Dose Naltrexone (LDN)
Not Yet RecruitingPhase 22026-11-01University of Alabama at Birmingham
NCT07874217Whole-body Cryotherapy in Those With Chronic Fatigue: A Feasibility Study
Cryotherapy
RecruitingNot applicable2026-10-05Oxford Brookes University
NCT07753122Controlled Trial of Hydrogen Water as a Treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Molecular Hydrogen Produced By A Metallic Magnesium Tablet, Consumed 3X A Day Dissolved In Water. Treatment Duration Is 16 Weeks.
RecruitingNot applicable2026-08-15Fred Friedberg
NCT07621068Hyperbaric Oxygen Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
Hyperbaric Oxygen Therapy (HBOT)
RecruitingNot applicable2026-07-19Assaf-Harofeh Medical Center
NCT07523113ME/CFS Brain Fog: Cognitive Rehabilitation Trial
Processing Speed Training, In-Session Instrumental Activities Of Daily Living Training, Transfer Package
RecruitingNot applicable2026-06-23University of Alabama at Birmingham
NCT07546539Photobiomodulation in Chronic Fatigue Syndrome
Photobiomodulation
RecruitingNot applicable2026-06-15University of Lahore
NCT07317401Investigating the Effects of Intermittent Hypoxia-Hyperoxia Treatment (IHHT) in People With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) to Improve Fatigue, Pain, and Quality of Life by Targeting Mitochondrial Dysfunction and Autonomic Nervous System Impairment
Intermittent Hypoxia-Hyperoxia Treatment
Not Yet RecruitingNot applicable2026-06-01University of Aarhus

Showing the 8 most recent of 11 trials with a 2026 start date.

All tracked trials: clinical trials tracker.

Therapeutic agents catalogue

The OSMF therapeutic-agents catalogue lists 195 agents with ME/CFS as a primary condition (of 609 agents overall). Evidence level is the catalogue's own coarse grading, assigned automatically from the number and type of linked studies and trials; it is not a GRADE assessment.

Agents by evidence levelPreliminaryPreliminary: 179179ModerateModerate: 1515AnecdotalAnecdotal: 11
Catalogue evidence grading: anecdotal, preliminary or moderate. No agent for any condition is graded higher than moderate.

Browse: therapeutics atlas and agents.

Biomarkers catalogued

The ME/CFS biomarker atlas (last edited 2026-06-29) holds 46 marker entries across 9 categories, citing 11 distinct DOIs: 13 reported elevated, 20 reduced and 13 with mixed or inconsistent findings. Direction is relative to the comparison group in the cited source (usually healthy controls) and a single entry can rest on one study.

Biomarkers by category and directionInflammatoryInflammatory - up: 4Inflammatory - mixed: 610MetabolicMetabolic - up: 2Metabolic - down: 7Metabolic - mixed: 110AutonomicAutonomic - up: 2Autonomic - down: 3Autonomic - mixed: 16ImmuneImmune - up: 2Immune - down: 2Immune - mixed: 15MitochondrialMitochondrial - down: 44FunctionalFunctional - down: 44AutoimmuneAutoimmune - up: 33NeurologicalNeurological - mixed: 22UrinaryUrinary - mixed: 22
ElevatedReducedMixed / inconsistentNot stated
Marker entries by atlas category, split by reported direction of change.
CategoryElevatedReducedMixedTotal
Inflammatory40610
Metabolic27110
Autonomic2316
Immune2215
Mitochondrial0404
Functional0404
Autoimmune3003
Neurological0022
Urinary0022

Full atlas: ME/CFS biomarker atlas.

Research cohorts

4 of the 32 cohorts in the OSMF post-acute infection syndrome (PAIS) cohort database relate to ME/CFS, together enrolling about 16,569 participants where a figure is recorded. This is a curated database, not a systematic census of cohorts.

CohortDesignEnrolledBiobankRegistration
DecodeME ME/CFS GWASregistry linkage15,579active—
UK ME/CFS Biobank (CureME, LSHTM)cross sectional632active—
Chicago adolescent post-mononucleosis cohort (Katz)prospective inception301unknown—
NIH Intramural ME/CFS Deep-Phenotyping Study (Walitt/Nath 2024)cross sectional57activeNCT02669212

Methods

This page was generated by scripts/build_reports.py on 21 November 2026 from the data snapshot described below. No number is entered by hand.

Limitations

Download the data

All inputs are public JSON files in the research-tracker repository, licensed for reuse with attribution.

Suggested citation

Open Source Medicine Foundation. ME/CFS: state of the evidence 2026 (year-to-date, generated 21 November 2026). Open Source Medicine Foundation; 2026. https://research.opensourcemed.info/reports/me-cfs-state-of-the-evidence-2026.html

For a stable reference, cite the generation date shown; the page is regenerated as data arrive. Weekly updates: subscribe on Substack or follow the digest RSS feed.

Disclaimer. This report is an automated description of a research database maintained by the Open Source Medicine Foundation. It is not a systematic review and not medical advice. Discuss any treatment decision with a qualified clinician.